Immunotherapy has improved the prognosis of many cancers, yet a large number of patients have demonstrated resistance to current immune checkpoint inhibitors. LAG-3 is an immune checkpoint expresse... Plain language summary Immunotherapy has increased survival rates for many cancer types; however, a large number of individuals experience resistance to this therapy and poor outcomes. Among the im... Tweetable abstract Coexpression of PD-1 and LAG-3 in solid or hematological cancers may be responsible for immunotherapy resistance; therefore, dual inhibition of PD-1 and LAG-3 may improve treatme...
1 December 2021 in Critical Reviews in Oncology/Hematology
Colorectal cancer (CRC) is ranked as the third most prevalent and the second deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, the number of CRC cases increased over th...
Gastric cancer (GC) ranks as the fifth most prevalent cancer and the fourth deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, GC represents about 4.8% of cancer cases w...
Locoregional, as well as metastatic renal cell carcinoma, tends to relapse after nephrectomy or metastasectomy. Adjuvant therapy seems to be an effective strategy to reduce the risk of recurrence. ... Plain language summary Advanced and metastatic kidney cancer often tend to relapse after surgery. Treatment maintenance after surgery could be an effective strategy to reduce the risk of recurrence...
The approval of adjuvant nivolumab and pembrolizumab following radical cystectomy and more recently perioperative durvalumab-based strategies represents a significant therapeutic advance in muscle-invasive bladder cancer (MIBC). However, a question that has received limited systematic attention concerns the optimal timing of immunotherapy initiation after surgery. Current recommendations are derived entirely from the eligibility windows of pivotal clinical trials, most notably CheckMate 274, AMBASSADOR and NIAGARA, which mandated randomization within approximately 120 days of cystectomy. These operational thresholds were designed to ensure postoperative recovery and were not prospectively validated as biologically optimal. This review critically examines the biological rationale underpinning timing considerations, appraises what clinical trials have actually studied, draws cautious parallels with adjuvant chemotherapy literature, and discusses how circulating tumour DNA (ctDNA) and minimal residual disease (MRD) detection may eventually redefine timing decisions. We conclude that no validated therapeutic window currently exists, that available evidence supports initiation within the studied timeframe when clinically feasible, and that prospective timing analyzes constitute a major unmet need in MIBC research.